CN101375846A - 一种鞣花酸超分子组合物及制备方法 - Google Patents
一种鞣花酸超分子组合物及制备方法 Download PDFInfo
- Publication number
- CN101375846A CN101375846A CNA2007100126372A CN200710012637A CN101375846A CN 101375846 A CN101375846 A CN 101375846A CN A2007100126372 A CNA2007100126372 A CN A2007100126372A CN 200710012637 A CN200710012637 A CN 200710012637A CN 101375846 A CN101375846 A CN 101375846A
- Authority
- CN
- China
- Prior art keywords
- ellagic acid
- cyclodextrin
- polyglycereol
- preparation
- emulsifying agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002079 Ellagic acid Polymers 0.000 title claims abstract description 67
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 title claims abstract description 67
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 title claims abstract description 67
- 235000004132 ellagic acid Nutrition 0.000 title claims abstract description 67
- 229960002852 ellagic acid Drugs 0.000 title claims abstract description 67
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 44
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 13
- 239000000084 colloidal system Substances 0.000 claims abstract description 7
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 15
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 11
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 11
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 11
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- -1 hydroxypropyl Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 4
- 238000001238 wet grinding Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 6
- 238000004090 dissolution Methods 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010051141 Myeloblastoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 108010012631 enduracidin A Proteins 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710012637 CN101375846B (zh) | 2007-08-30 | 2007-08-30 | 一种鞣花酸超分子组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710012637 CN101375846B (zh) | 2007-08-30 | 2007-08-30 | 一种鞣花酸超分子组合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101375846A true CN101375846A (zh) | 2009-03-04 |
CN101375846B CN101375846B (zh) | 2013-07-10 |
Family
ID=40419691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710012637 Expired - Fee Related CN101375846B (zh) | 2007-08-30 | 2007-08-30 | 一种鞣花酸超分子组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101375846B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103830744A (zh) * | 2014-03-26 | 2014-06-04 | 张红梅 | 一种缓释型鞣花酸-环糊精复合物及其制备方法 |
CN106421809A (zh) * | 2016-09-30 | 2017-02-22 | 合肥职业技术学院 | 一种石榴鞣花酸包合物的制备方法及产品 |
CN108324686A (zh) * | 2018-03-16 | 2018-07-27 | 枣庄学院 | 一种鞣花酸自微乳及其制备方法 |
JP2019504042A (ja) * | 2015-12-21 | 2019-02-14 | 広州市香雪製薬股▲ふん▼有限公司Guangzhou Xiangxue Pharmaceutical Co., Ltd. | 経口製剤およびその製造方法 |
JP2019506377A (ja) * | 2015-12-21 | 2019-03-07 | 広州市香雪製薬股▲ふん▼有限公司Guangzhou Xiangxue Pharmaceutical Co., Ltd. | 薬物包接化合物、その製剤、およびそのための製造方法 |
CN110123664A (zh) * | 2019-05-22 | 2019-08-16 | 中科萱嘉医养(珠海)健康科技有限公司 | 一种含有益母草碱的超分子组合物或包合物及其制备方法与应用 |
US20190323045A1 (en) * | 2016-12-26 | 2019-10-24 | Daicel Corporation | Method for producing urolithins |
CN111920766A (zh) * | 2020-07-28 | 2020-11-13 | 中南林业科技大学 | 一种鞣花酸分散体系及其制备方法 |
CN114712524A (zh) * | 2022-04-09 | 2022-07-08 | 湖州嘉亨实业有限公司 | 一种羟丙基环糊精包合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05331183A (ja) * | 1992-05-29 | 1993-12-14 | Kikkoman Corp | エラグ酸配糖体及びその製造法 |
CN1317937A (zh) * | 1998-09-15 | 2001-10-17 | 韩国生命工学研究院 | 用于预防或治疗与血脂水平升高相关的疾病的含有天然酚类化合物的组合物 |
-
2007
- 2007-08-30 CN CN 200710012637 patent/CN101375846B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05331183A (ja) * | 1992-05-29 | 1993-12-14 | Kikkoman Corp | エラグ酸配糖体及びその製造法 |
CN1317937A (zh) * | 1998-09-15 | 2001-10-17 | 韩国生命工学研究院 | 用于预防或治疗与血脂水平升高相关的疾病的含有天然酚类化合物的组合物 |
Non-Patent Citations (3)
Title |
---|
李庆等: "新型天然抗氧化剂-鞣花酸", 四川食品与发酵37 4 * |
毕殿洲: "药剂学", 31 December 2000, 中国医药科技出版社 * |
陈笳鸿等: "紫外分光光度法测定鞣花酸含量的研究", 生物质化学工程41 3 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103830744A (zh) * | 2014-03-26 | 2014-06-04 | 张红梅 | 一种缓释型鞣花酸-环糊精复合物及其制备方法 |
CN103830744B (zh) * | 2014-03-26 | 2016-03-09 | 张红梅 | 一种缓释型鞣花酸-环糊精复合物及其制备方法 |
JP2019506377A (ja) * | 2015-12-21 | 2019-03-07 | 広州市香雪製薬股▲ふん▼有限公司Guangzhou Xiangxue Pharmaceutical Co., Ltd. | 薬物包接化合物、その製剤、およびそのための製造方法 |
US11071737B2 (en) | 2015-12-21 | 2021-07-27 | Guangzhou Xiangxue Pharmaceutical Co., Ltd. | Drug inclusion complex, preparation thereof, and preparation method thereof |
US11007141B2 (en) | 2015-12-21 | 2021-05-18 | Guangzhou Xiangxue Pharmaceutical Co., Ltd. | Oral preparation and preparation method thereof |
JP2019504042A (ja) * | 2015-12-21 | 2019-02-14 | 広州市香雪製薬股▲ふん▼有限公司Guangzhou Xiangxue Pharmaceutical Co., Ltd. | 経口製剤およびその製造方法 |
CN106421809B (zh) * | 2016-09-30 | 2018-07-10 | 合肥职业技术学院 | 一种石榴鞣花酸包合物的制备方法及产品 |
CN106421809A (zh) * | 2016-09-30 | 2017-02-22 | 合肥职业技术学院 | 一种石榴鞣花酸包合物的制备方法及产品 |
US20190323045A1 (en) * | 2016-12-26 | 2019-10-24 | Daicel Corporation | Method for producing urolithins |
US12006524B2 (en) * | 2016-12-26 | 2024-06-11 | Daicel Corporation | Method for producing urolithins |
CN108324686B (zh) * | 2018-03-16 | 2020-01-10 | 枣庄学院 | 一种鞣花酸自微乳及其制备方法 |
CN108324686A (zh) * | 2018-03-16 | 2018-07-27 | 枣庄学院 | 一种鞣花酸自微乳及其制备方法 |
CN110123664A (zh) * | 2019-05-22 | 2019-08-16 | 中科萱嘉医养(珠海)健康科技有限公司 | 一种含有益母草碱的超分子组合物或包合物及其制备方法与应用 |
CN111920766A (zh) * | 2020-07-28 | 2020-11-13 | 中南林业科技大学 | 一种鞣花酸分散体系及其制备方法 |
CN114712524A (zh) * | 2022-04-09 | 2022-07-08 | 湖州嘉亨实业有限公司 | 一种羟丙基环糊精包合物及其制备方法 |
CN114712524B (zh) * | 2022-04-09 | 2024-02-13 | 湖州嘉亨实业有限公司 | 一种羟丙基环糊精包合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101375846B (zh) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101375846B (zh) | 一种鞣花酸超分子组合物及制备方法 | |
CN106389453B (zh) | 黄酮糖苷组合物 | |
Wang et al. | Host-guest inclusion system of scutellarein with 2-hydroxypropyl-beta-cyclodextrin: preparation, characterization, and anticancer activity | |
CN104069348A (zh) | 黄精提取物及其制备方法与应用 | |
Zu et al. | The high water solubility of inclusion complex of taxifolin-γ-CD prepared and characterized by the emulsion solvent evaporation and the freeze drying combination method | |
Li et al. | Synthesis, characterization, solubilization, cytotoxicity and antioxidant activity of aminomethylated dihydroquercetin | |
CN101112409A (zh) | 蒲公英中酚酸类有效部位的制备及其抑制流感病毒的用途 | |
CN106749729B (zh) | 一种鹿药多糖及其制备方法和应用 | |
Nosáľová et al. | Antitussive arabinogalactan of Andrographis paniculata demonstrates synergistic effect with andrographolide | |
Kale et al. | Decreased B16F10 melanoma growth and impaired tumour vascularization in BDF1 mice with quercetin‐cyclodextrin binary system | |
Öztürk et al. | Synthesis, characterization, antioxidant activity of Quercetin, Rutin and Quercetin-Rutin incorporated β-cyclodextrin inclusion complexes and determination of their activity in NIH-3T3, MDA-MB-231 and A549 cell lines | |
Islam et al. | The role of natural and semi-synthetic compounds in ovarian cancer: Updates on mechanisms of action, current trends and perspectives | |
Sevimli-Gur et al. | Cytotoxicity screening of supercritical fluid extracted seaweeds and phenylpropanoids | |
CN104292203B (zh) | 一种异香豆素类化合物及其制备方法和应用 | |
KR102023808B1 (ko) | 신남알데하이드 또는 신남산을 생성하는 혼성 항암 전구약물 및 이의 제조방법 | |
CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
CN111437283A (zh) | β1,4-半乳糖基转移酶抑制剂在制备治疗癌症的药物中的应用 | |
CN102219782B (zh) | 一种从天然产物中提取分离牡荆素和异牡荆素的方法 | |
CN104622971A (zh) | 一种抗糖尿病活性的药物组合物及其制备方法 | |
Xie et al. | Optimization of ellagic acid extraction from blueberry pulp through enzymatic hydrolysis combined with ultrasound-assisted organic solvent | |
CN101757640B (zh) | 一种鹰嘴豆异黄酮与环糊精包合物的制备 | |
Chen et al. | Preparation, characterization and solubilization evaluation of two novel host-guest complexes based on two different functional groups of modified β-cyclodextrins and 20 (S)-protopanaxatriol | |
WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
CN101239058A (zh) | 原花青素类化合物用于制备防治幽门螺杆菌相关性胃炎的药物和保健食品 | |
CN114712522A (zh) | 连翘苷元与环糊精包合物或环糊精衍生物的包合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Lixin Document name: Notification that Application Deemed not to be Proposed |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LIAONING WANJIA PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: SHENYANG HAOTIAN WANJIA PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150211 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 110015 BENXI, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150211 Address after: 110015 bio pharmaceutical industry park, Benxi Economic Development Zone, Liaoning Patentee after: LIAONING WANJIA MEDICAL TECHNOLOGY Co.,Ltd. Address before: 110015 Liaoning province in Dongling District of Shenyang City fengle Street No. 86 Patentee before: Shenyang Haotian Wanjia Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190730 Address after: Room A101, 18 ShuangD Fifth Street, Dalian Economic and Technological Development Zone, Liaoning 116600 Patentee after: Suqian Medical Technology Co.,Ltd. Address before: 110015 Biomedical Industrial Park, Benxi Economic Development Zone, Liaoning Province Patentee before: LIAONING WANJIA MEDICAL TECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130710 |